457 related articles for article (PubMed ID: 19694996)
1. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Ambruso DR; Thurman G; Marschner S; Goodrich RP
Transfusion; 2009 Dec; 49(12):2631-6. PubMed ID: 19694996
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
Perez-Pujol S; Tonda R; Lozano M; Fuste B; Lopez-Vilchez I; Galan AM; Li J; Goodrich R; Escolar G
Transfusion; 2005 Jun; 45(6):911-9. PubMed ID: 15934989
[TBL] [Abstract][Full Text] [Related]
3. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study.
Picker SM; Steisel A; Gathof BS
Transfus Apher Sci; 2009 Apr; 40(2):79-85. PubMed ID: 19233725
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology.
Li J; Lockerbie O; de Korte D; Rice J; McLean R; Goodrich RP
Transfusion; 2005 Jun; 45(6):920-6. PubMed ID: 15934990
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma.
Tonnetti L; Proctor MC; Reddy HL; Goodrich RP; Leiby DA
Transfusion; 2010 May; 50(5):1019-27. PubMed ID: 20030791
[TBL] [Abstract][Full Text] [Related]
6. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction.
Picker SM; Oustianskaia L; Schneider V; Gathof BS
Vox Sang; 2009 Jul; 97(1):26-33. PubMed ID: 19302416
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction.
AuBuchon JP; Herschel L; Roger J; Taylor H; Whitley P; Li J; Edrich R; Goodrich RP
Transfusion; 2005 Aug; 45(8):1335-41. PubMed ID: 16078923
[TBL] [Abstract][Full Text] [Related]
8. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology.
Ostrowski SR; Bochsen L; Salado-Jimena JA; Ullum H; Reynaerts I; Goodrich RP; Johansson PI
Transfusion; 2010 Oct; 50(10):2210-9. PubMed ID: 20456708
[TBL] [Abstract][Full Text] [Related]
9. Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro.
Zeddies S; De Cuyper IM; van der Meer PF; Daal BB; de Korte D; Gutiérrez L; Thijssen-Timmer DC
Transfusion; 2014 Sep; 54(9):2292-300. PubMed ID: 24689812
[TBL] [Abstract][Full Text] [Related]
10. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units.
Picker SM; Steisel A; Gathof BS
Transfusion; 2008 Aug; 48(8):1685-92. PubMed ID: 18513255
[TBL] [Abstract][Full Text] [Related]
11. Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.
Picker SM; Tauszig ME; Gathof BS
Transfusion; 2012 Mar; 52(3):510-6. PubMed ID: 21981030
[TBL] [Abstract][Full Text] [Related]
12. Real-time measurement of platelet shape change by light scattering under riboflavin and ultraviolet light treatment.
Terada C; Shiba M; Satake M; Tadokoro K
Transfusion; 2016 Mar; 56(3):587-95. PubMed ID: 26536611
[TBL] [Abstract][Full Text] [Related]
13. White blood cell inactivation after treatment with riboflavin and ultraviolet light.
Marschner S; Fast LD; Baldwin WM; Slichter SJ; Goodrich RP
Transfusion; 2010 Nov; 50(11):2489-98. PubMed ID: 20529002
[TBL] [Abstract][Full Text] [Related]
14. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage.
Schubert P; Culibrk B; Coupland D; Scammell K; Gyongyossy-Issa M; Devine DV
Transfusion; 2012 Feb; 52(2):397-408. PubMed ID: 21827504
[TBL] [Abstract][Full Text] [Related]
15. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies.
Picker SM; Schneider V; Gathof BS
Transfusion; 2009 Jun; 49(6):1224-32. PubMed ID: 19220821
[TBL] [Abstract][Full Text] [Related]
16. Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction.
Tauszig ME; Picker SM; Gathof BS
Transfus Apher Sci; 2012 Feb; 46(1):33-7. PubMed ID: 22119364
[TBL] [Abstract][Full Text] [Related]
17. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology.
Mirasol Clinical Evaluation Study Group
Transfusion; 2010 Nov; 50(11):2362-75. PubMed ID: 20492615
[TBL] [Abstract][Full Text] [Related]
18. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days.
Cookson P; Thomas S; Marschner S; Goodrich R; Cardigan R
Transfusion; 2012 May; 52(5):983-94. PubMed ID: 22014032
[TBL] [Abstract][Full Text] [Related]
19. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment.
Lin L; Conlan MG; Tessman J; Cimino G; Porter S
Transfusion; 2005 Oct; 45(10):1610-20. PubMed ID: 16181212
[TBL] [Abstract][Full Text] [Related]
20. Effects of riboflavin and ultraviolet light treatment on platelet thrombus formation on collagen via integrin αIIbβ3 activation.
Terada C; Mori J; Okazaki H; Satake M; Tadokoro K
Transfusion; 2014 Jul; 54(7):1808-16. PubMed ID: 24506417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
